@RetamozoSole @RheumNow @Reumaclinic @MAS_Clinic @hospitalclinic #ACR20 Thanks for sharing! but our data show that patients under anti-Cytokine therapy in monotherapy at baseline (specifically anti-IL6 -IL12/23 and -IL17) or under JAKinh were ⬇️LESS likely to be admitted (OR 0.15; 95% CI 0.03-0.66; p=0.012) 📍Limitations: small number of pts https://t.co/zeLzrNLeDQ

@RheumNow #acr20 abs0876 gender differences AS and nrSpA from 3 RCT IXE trials: F more likely to be older, have more nocturnal BP, peripheral pain&fatigue. M have higher CRP & +HLAB27. Ant uveitis > in M w/AS (23.8% vs. 17.9%) but > common in F w/ nr-axSpA (15.2% vs. 7.1%). https://t.co/HZa7AfWbBh

Gender differences in Axial Spondyloarthritis patients Pooled data from 3 Ixekizumab studies Women: 1⃣older at disease onset (30 vs. 26) 2⃣Longer symptom duration (17.8 yrs vs. 16.7 yrs) 3⃣More peripheral joint pain and lower HLA-B27 @RheumNow #ACR20 Abs#0876 https://t.co/qGHXApi0Ko

Australian study looking at clinical outcomes following in-class switching vs switching MOA. Rapid effect of IL-17i and JAKi with PsA rated highly. This study highlights ever-growing need for precision medicine based on domain. #ABS09003 #ACR20 @RheumNow https://t.co/7qKH6aw6f0

• Changing Patterns of Use of Biologic/Targeted Synthetic DMARDs in Psoriatic Art…

Concise, educational and useful table by @ArleneBravoMD presented by Dr. Arthur Kavanaugh in his PsA clinical trials update. Beautiful organization of targeted therapy in multiple autoimmune diseases. Bedside to Bench. @RheumNow #ACR20 https://t.co/PIvvsQWs0J

Secukinumab has been used to treat spinal involvement in axial SpA. Secukinumab led to significant improvements in symptoms of peripheral arthritis in pts with AS. Significant improvements were seen in both tender and swollen joints @RheumNow #ACR20 Abstr#366